Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study

Toni K. Choueiri, Laurence Albigès, Philippe Barthélémy, Roberto Iacovelli, Sheik Emambux, Javier Molina‐Cerrillo, Benjamin Garmezy, Pedro C. Barata, Arnab Basu, María T. Bourlon, Helen Moon, Raffaele Ratta, Rana R. McKay, Alex Chehrazi‐Raffle, Hans J. Hammers, Daniel Y.C. Heng, Edgar Braendle, Kathryn E. Beckermann, Bradley A. McGregor, Robert J. Motzer